NCT07076277
Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro
Enrolling by Invitation
NAAges 18+InterventionalTreatmentBrian ShaferInvestigator-initiated
~346 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Clareon PanOptix Pro and Clareon Vivity Intraocular LensClareon PanOptix Pro Intraocular Lenses
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Binocular Best-Corrected Distance Visual Acuity (BCDVA) at 4 meters
Measured over 3 months post-operative visit
Conditions
Where it's being run
5 sites across 4 statesPennsylvania2
Maryland1
Minnesota1
Montana1
Study leadership
- Brian Shafer, MD · PRINCIPAL_INVESTIGATOR · Shafer Vision Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Binocular Best-Corrected Distance Visual Acuity (BCDVA) at 4 meters3 months post-operative visit
Binocular BCDVA measured in logMAR under photopic conditions (85 cd/m²) at 4 m using standardized ETDRS charts with the M\&S Clinical Trial Suite (CTS). Non-inferiority margin of 0.1 logMAR between treatment arms.